Combining therapies targeting multiple toll-like receptors

Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C424S130100, C424S141100

Reexamination Certificate

active

08029794

ABSTRACT:
The invention relates generally to compositions that contain multiple antibodies, e.g., multiple neutralizing antibodies, that immunospecifically bind to one or more toll-like receptors, e.g., two or more toll-like receptors, and methods of using these compositions in the treatment of inflammatory disorders.

REFERENCES:
patent: 6444206 (2002-09-01), Leturcq
patent: 7271248 (2007-09-01), Hardiman et al.
patent: 7312320 (2007-12-01), Elson
patent: 2005/0265998 (2005-12-01), Elson
patent: 2008/0118514 (2008-05-01), Elson
patent: WO 03/013440 (2003-02-01), None
patent: WO 2005/028509 (2005-03-01), None
patent: WO 2005/047330 (2005-05-01), None
Meng et al. The Journal of Clinical Investigation 2004, 113:1473-1481.
Strom et al. (in Therapeutic Immunology, Austen et al. (Ed.) Blackwell Science, Cambridge MA, 1996; see pp. 451-456).
Akashi et al., “Cutting edge: Cell surface expression and lipopolysaccharide signaling via the Toll-like receptor 4-MD-2 complex on mouse peritoneal macrophages,” J. Immunol., vol. 164(7): 3471-3475 (2000).
Akashi et al., “Lipopolysaccharide interaction with cell surface Toll-like receptor 4-MD-2: Higher affinity than that with MD-2 or CD14,” J. Exp. Med., vol. 198(7): 1035-1042 (2003).
Akira et al., “Toll-like receptor signaling,” Nature Reviews Immunology, vol. 4: 491-511 (2004).
Backhed et al, “TLR4-dependent recognition of lipopolysaccharide by epithelial cells requires sCD14,” Cellular Microbiology, vol. 4(8): 493-501 (2002).
Buell et al., “Blockade of human P2X7 receptor function with a monoclonal antibody.” Blood 92: 3521-3528 (1998).
Devaney et al., “Neutrophil elastase up-regulates interleukin via toll-like receptor 4,” FEBS Letters, vol. 544 (1-3): 129-132 (2003).
GenBank Accession No. AAH20690.1 “Lymphocyte antigen 96 [Homo sapiens]”.
GenBank Accession No. BAA78717.1 “MD-2 [Homo sapiens]”.
GenBank Accession No. CAH72619.1 “toll-like receptor 4 [Homo sapiens]”.
GenBank Accession No. CAH72620 “toll-like receptor 4 [Homo sapiens]”.
GenBank Accession No. NP—003254.2 “toll-like receptor 1 [Homo sapiens]”.
GenBank Accession No. NP—003255.2 “toll-like receptor 2 [Homo sapiens]”.
GenBank Accession No. NP—003259.2 “toll-like receptor 5 [Homo sapiens]”.
GenBank Accession No. NP—006059.2 “toll-like receptor 6 [Homo sapiens]”.
GenBank Accession No. NP—056179, “MD-2 protein [Homo sapiens]”.
GenBank Accession No. Q9Y6Y9, “RecName: Full=Lymphocyte antigen 96; AltName: Full=Protein MD-2; AltName: Full=ESPO-1; Flags: Precursor”.
Ishida et al., “Hypoxia diminishes Toll-like Receptor 4 expression through reactive oxygen species generated by mitochondria in endothelial cells,” J. Immunol., vol. 169(4): 2069-2075 (2002).
Johnson et al., “Activation of mammalian Toll-like receptors by endogenous agonists” Crit. Rev. Immunol., 23(1-2):15-44 (2003).
Jones and Bendig, “Rapid PCR-cloning of full-length mouse immunoglobulin variable regions.” Biotechnology (N.Y.), 9: 88-89 (1991).
Kammann et al., “Rapid insertional mutagenesis of DNA by polymerase chain reaction (PCR),” Nucleic Acids Res.. vol. 17: 5404 (1989).
Kawasaki et al., “Identification of mouse MD-2 residues important for forming the cell surface TLR4-MD-2 complex recognized by anti-TLR4-MD2 antibodies, and for conferring LPS and taxol responsiveness on mouse TLR4 by alanine-scanning mutagenesis,” J. Immunol., vol. 170(1): 413-420 (2003).
Kirkland et al., “Analysis of Lipopolysaccharide Binding by CD14,” J. Biol. Chem., vol. 268(33): 24818-24823(1993).
Kolbinger et al., “Humanization of a mouse anti-human IgE antibody: a potential therapeutic for IgE-mediated allergies” Protein Eng. 6, 971-980, 1993).
Lakhani et al., “Toll-like receptor signaling in sepsis” Curr. Opin. Pediatr. 15: 278-282 (2003).
Lenhardt et al., “Activation of innate immunity in the CNS triggersneurodegeneration through a Toll-like receptor 4-dependent pathway,” PNAS, vol. 100(14): 8514-8519 (2003).
Medzhitov et al., Nature, “A human homologue of theDrosophilaToll protein signals activation of adaptive immunity,” vol. 388(6640):394-7 (1997).
Meng et al., “Antagonistic antibody prevents toll-like receptor 2-driven lethal shock-like syndromes,” J. Clin. Invest., vol. 113: 1473-1481 (2004).
Miyake, “Endotoxin recognition molecules MD-2 and Toll-like Receptor 4 as potential targets for therapeutic intervention of endotoxin shock,” Current Drug Targets: Inflammation and Allergy, vol. 3(3): 291-297 (2004).
Miyake, “Innate recognition of lipopolysaccharide by CD14 and toll-like receptor 4-MD-2: unique roles for MD-2,” International Immunopharmacology, vol. 3(1): 1199-128 (2003).
Mizel et al., “Induction of macrophage nitric oxide production by gram-negative flagellin involves signaling via heteromeric toll-like receptor 5/toll-like receptor 4 complexes,” J. Immunol., vol. 170: 6217-3223 (2003).
Nijhuis et al, “Endothelial cells are main producers of Interleukin 8 through Toll-like receptor 2 and 4 signaling during bacterial infection in leukopenic cancer patients,” Clinical and Diagnostic Laboratory Immunology, vol. 10(4): 558-563 (20030.
O'Neill, “Therapeutic targeting of Toll-like receptors for inflammatory and infectious diseases” Curr. Opin. Pharmacol. 3: 396-403 (2003).
Ohashi et al., “Cutting Edge: Heat Shock Protein 60 is a Putative Endogenous Ligand of the Tdl-Like Receptor-4 Complex,” J. Immunol., vol. 164: 558-561 (2000).
Okamura et al., “The Extra Domain A of Fibronectin Activates Toll-like Receptor 4,” J. Biol. Chem. vol. 276(13): 10229-10233 (2001).
Pasterkamp et al., “Role of Toll-like Receptor 4 in the initiation and progression of atherosclerotic disease,” Eur. J. Clin. Invest., vol. 34(5): 328-334 (2004).
Pivarcsi et al., “Expression and Function of Toll-like Receptors 2 and 4 in Human Keratinocytes,” International Immunology, vol. 15(6): 721-730 (2003).
Pugin et al., “Soluble MD-2 activity in plasma from patients with severe sepsis and septic shock,” Blood, vol. 104(13): 4071-4079 (2004).
Rock et al., “A family of human receptors structurally related toDrosophilaToll,” Proc. Natl. Acad. Sci. USA, vol. 95: 588-593 (1998).
Santa Cruz Biotechnology, Inc., “TLR (H-80): sc-10741”, catalog page for TLR4 (H-80), a rabbit polyclonal antibody raised against amino acids 242-321 of TLR4 of human origin.
Sato et al., “Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth,” Cancer Res. vol. 53: 851-856 (1993).
Shimazu et al., “MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4,” J. Exp. Med., vol. 189(11): 1777-1782 (1999).
Takeda et al., “Toll-like receptors” Annu. Rev. Immunol., 21: 335-76 (2003).
Uehori et al., “Simultaneous blocking of human Toll-like receptors 2 and 4 suppresses myeloid dendritic cell activation induced byMycobacterium bovisbacillus Calmette-Guérin peptidoglycan,” Infect. Immun., vol. 71(8): 4238-4249 (2003).
Weingarten et al., “Interactions of lipopolysaccharide with neutrophils in blood via CD14,” J. Leukocyte Biol., vol. 53: 518-524 (1993).
Yang et al., “Cellular events mediated by lipopolysaccharide-stimulated Toll-like receptor 4,” J. Biol. Chem., vol. 275(27): 20861-20866 (2000).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Combining therapies targeting multiple toll-like receptors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Combining therapies targeting multiple toll-like receptors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combining therapies targeting multiple toll-like receptors will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4260184

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.